Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness
Other Report Findings of Adverse Effects
The rate of adverse effects increases with increased doses of darifenacin, fesoterodine, oxybutynin, and solifenacin. (Dosage effects of tolterodine and trospium are not reported.) The strength of evidence for this finding is high.
Transdermal and controlled-release forms of oxybutynin have lower rates of adverse effects, but a dose response for adverse effects is still found with these formulations. The strength of evidence for this finding is low.
Fifty percent of women stop treatment with drugs within 1 year. The strength of evidence for this finding is high.
Keywords: urinary incontinence | stress incontinence | urge incontinence | urgency incontinence | mixed incontinence | continence | adverse effects | darifenacin | fesoterodine | oxybutynin | solifenacin | discontinuation | dosage | trospium | tolterodine
- Shamliyan T, Wyman J, Sainfort F, et al. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Comparative Effectiveness Review No. 36 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 11(12)-EHC074-EF. Available at www.effectivehealthcare.ahrq.gov/ui.cfm.
Your slide tray is being processed.